2017 Public Outcomes Report

Commission on Cancer - Cancer Program Practice Profile Reports

As a Commission on Cancer (CoC)-accredited cancer program, Fairview Ridges Hospital ensures that patients with cancer are treated according to nationally accepted measures.

Measures for Quality of Cancer Care

Each year, CoC-accredited programs are required to review their quality of patient care using the Cancer Program Practice Profile Reports (CP3R).

The CP3R analyzes Fairview Ridges Hospital performance compared to the national standard of care for selected cancer sites. The CP3R also provides aggregate feedback for comparison with similar CoC-accredited cancer programs.

The CoC partners with internal and external clinical experts to develop quality measures. The Fairview Ridges Hospital cancer registry collects the necessary data to assess and monitor concordance with the measures. The results are reported to the National Cancer Data Base (NCDB), a joint program of the American College of Surgeons (ACoS) and the American Cancer Society (ACS). NCDB is a clinical oncology outcomes database for more than 1,500 commission-accredited cancer programs.

This report focuses on quality measures for breast and colon cancer. The report includes patients diagnosed in 2015. Fairview Ridges meets or exceeds CoC expected performance rates (EPR) for five out of five measures compared to Minnesota and all CoC approved programs.

View the report

Commission on Cancer Overview

The Commission on Cancer (CoC), a program of the American College of Surgeons (ACoS), recognizes cancer care programs for their commitment to providing comprehensive, high-quality, and multidisciplinary patient centered care.

The CoC accreditation program is voluntary and encourages hospitals to improve quality of patient care through various cancer-related programs. These programs address the full continuum of cancer from prevention through hospice and end-of-life care, or survivorship and quality of life.

Fairview Ridges Hospital has maintained accreditation with the Commission on Cancer since 2008.